Clik here to view.
Sengenics, a Leading Commercial Stage Precision Medicine Focused Company,...
SINGAPORE Sengenics, a leading commercial stage precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, has been invited to present at the Biotech Showcase™ during...
View ArticleClik here to view.
山东方坦思宣布与杨森制药达成许可协议将开发抗IL-17A单克隆抗体并使其商业化
2019年12月17日[美国东部时间 (美国商业资讯)– 山东方坦思生制药有限公司（“方坦思”）今日宣布与强生公司旗下的一家杨森制药公司（“杨森”）签订独家许可、开发和商业化协议，在中华人民共和国（“中国”）包括香港特别行政区（“香港”）、澳门特别行政区（“澳门”）、台湾区域（“台湾”） 和韩国开发含有抗IL-17A单克隆抗体的医药产品并使其商业化。...
View ArticleClik here to view.
Shandong Fontacea Announces License Agreement with Janssen to Develop and...
JINAN, Shandong, People’s Republic of China Shandong Fontacea Pharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license, development and commercialization...
View ArticleClik here to view.
Company Profile for Shandong Fontacea Pharmaceutical Co. Ltd.
About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market,...
View ArticleClik here to view.
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Vantage 2020 Preview: Strong Sales and Product Launches Set the Stage for...
LONDON & BOSTON & TOKYO Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage...
View ArticleClik here to view.
Turnstone Biologics Announces Global Collaboration and License Agreement with...
NEW YORK Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies, today announced a strategic collaboration with Takeda Pharmaceutical Company...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals...
View ArticleClik here to view.
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved...
View ArticleClik here to view.
Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and...
BOSTON Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership...
View ArticleClik here to view.
インヴィクロがマシュー・シルビア博士の新最高経営責任者への任命とジャック・ホッピン博士のコニカミノルタプレシジョンメディシン社長への任命を発表
ボストン （ビジネスワイヤ） —...
View ArticleClik here to view.
Invicro LLC宣布Matthew Silva博士为新任首席执行官，Jack Hoppin博士被任命为Konica Minolta...
波士顿 (美国商业资讯)–柯尼卡美能达(Konica Minolta)旗下公司Invicro LLC今天宣布，Matthew Silva博士已被任命为公司新任首席执行官。Silva博士将负责公司的日常领导工作，并将加入Invicro董事会，即刻生效。Invicro联合创始人Jack Hoppin博士将不再担任Invicro首席执行官，转而出任Konica Minolta Precision...
View ArticleClik here to view.
Starpharma: Commencement of Phase 1 Trial for AZD0466 Utilising DEP® Delivery...
MELBOURNE, Australia Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) and the first...
View ArticleClik here to view.
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate,...
View ArticleClik here to view.
Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue,...
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James...
View ArticleClik here to view.
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License...
ROCKVILLE, Md. & FOSTER CITY, Calif. & HANGZHOU, China GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innovative...
View ArticleClik here to view.
MaveriX Oncology to Present at China Showcase 2020 and Biotech Showcase™ 2020...
PALO ALTO, Calif. MaveriX Oncology, Inc., a development-stage biotechnology company with a proprietary pipeline of targeted small-molecule chemo-immuno-therapeutics for the treatment of a broad...
View ArticleClik here to view.
Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer...
STRASBOURG, France & TOKYO Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO:...
View ArticleClik here to view.
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized...
STRASBOURG, France & TOKYO Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and...
View ArticleClik here to view.
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
SIOUX FALLS, S.D. SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple...
View Article